Loading organizations...
§ Private Profile · 484 9th St, Oakland, California 94607, US
Riffyn is a company.
Riffyn has raised $19.6M across 2 funding rounds.
Key people at Riffyn.
Riffyn has raised $19.6M in total across 2 funding rounds.
Riffyn develops cloud-based software streamlining scientific research and development. Its core offering, the Riffyn SDE (Scientific Development Environment), enables intelligent process development, experiment design, and advanced data analytics. The platform integrates research protocols, experimental parameters, and results into a unified system, addressing data fragmentation and enhancing reproducibility.
Timothy Gardner founded Riffyn in 2014. His experience in life science and high-performance computing revealed significant challenges in scientific data management and experimental reproducibility. This insight led him to develop a system designed to standardize and optimize scientific experimentation, accelerating research and development outcomes.
Riffyn's platform supports R&D and process development across diverse scientific industries, including biopharma, biotech, and advanced materials. The company's vision centers on accelerating scientific discovery and product innovation by equipping scientists with robust tools for efficient, organized, and reproducible experimentation, empowering advancements.
Key people at Riffyn.
Riffyn has raised $19.6M across 2 funding rounds. Most recently, it raised $15.0M Series B in May 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 29, 2019 | $15M Series B | Joey Mason | O'Reilly AlphaTech Ventures, Plug And Play Ventures, Maura Fitzpatrick | Announced |
| Jul 6, 2016 | $4.6M Venture Round | — | Bioeconomy Capital, O'Reilly AlphaTech Ventures, Hartmut Klocker | Announced |
Riffyn has raised $19.6M in total across 2 funding rounds.
Riffyn's investors include Joey Mason, O'Reilly AlphaTech Ventures, Plug and Play Ventures, Maura Fitzpatrick, Bioeconomy Capital, Hartmut Klocker.
Riffyn is a cloud-based software company that builds Riffyn Nexus, a process data system designed for scientific R&D in life sciences, biopharma, and manufacturing. It serves R&D organizations—from small labs of 2 scientists to enterprises like BASF and Novozymes—solving data fragmentation, poor data quality, ambiguous process design, and collaboration barriers by organizing data around R&D and manufacturing processes for real-time integration, analysis, and machine learning readiness.[1][2][5][6] This enables 2X faster development cycles and 4X productivity gains, accelerating workflows from discovery to manufacturing while supporting Design-Build-Test-Learn cycles and tools like JMP, Python, and DoE modeling.[2][4][5]
Founded in 2014 in Oakland, California, Riffyn has gained recognition in Gartner reports for bioprocessing and enterprise laboratory informatics, helping users predict yields, purities, and costs through ML-enabled data analytics.[1][2]
Riffyn was founded in 2014 in Oakland, California, to tackle persistent data challenges in scientific R&D, launching Riffyn Nexus as the world's first Process Data System.[1][2] The idea emerged from the need to defragment data across files, instruments, LIMS, and automation systems, inspired by Total Quality's Design-Build-Test-Learn cycle and a process-centric approach to make data always ready for machine learning.[2][5]
Early traction came from supporting diverse teams, from small labs to hundreds of scientists, with a key partnership alongside Novozymes—the world's largest enzyme and microbial tech provider—scaling to thousands of users amid challenges like massive data volumes in agriculture, energy, and renewables.[6] Pivotal moments include upgrades like Nexus v4.2 for real-time data validation and testimonials from BASF's R&D Director on automation scaling.[4]
Riffyn stands out in lab informatics through its process-centric platform, contrasting traditional ELN and LIMS by using R&D workflows as the core for data storage, analysis, and UI.[2][5] Key strengths include:
These features deliver quantifiable gains like 2X faster market entry and 4X productivity.[4][5]
Riffyn rides the digital transformation wave in biopharma and life sciences R&D, where labs seek "Lab of the Future" capabilities amid exploding data from automation, high-throughput screening, and AI-driven discovery.[2] Timing aligns with industry shifts to process intelligence, multivariate analytics, and ML for bioprocessing—Gartner-highlighted trends predicting yields and optimizing value chains from upstream to downstream.[1][2]
Market forces like rising R&D costs, regulatory demands for data integrity, and enzyme/microbial tech expansions (e.g., Novozymes' renewables push) favor Riffyn's real-time, scalable solution.[4][6] It influences the ecosystem by enabling faster innovation in precision oncology, drug discovery, and sustainable manufacturing, bridging small labs to enterprises and accelerating AI adoption in science.[1][6]
Riffyn is poised to expand as Siemens integrates Riffyn X for enterprise recipe management, signaling deeper penetration in pharma manufacturing and potential growth via acquisitions or partnerships.[3] Trends like AI/ML ubiquity in bioprocessing, CAR-T scaling, and sustainable biotech will amplify demand for its data flywheel, potentially evolving into a standard for "Intelligent Process Development."[4]
Its influence may grow by powering global R&D consortia, with upgrades like v4.2 paving the way for even larger-scale automation—ultimately making machine learning in science routine and cementing Riffyn's role in 2X-faster innovation cycles.[5]
